2,4-Diaminopyrimidine inhibitors of c-Met kinase bearing benzoxazepine anilines

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 2, 2011, Pages 660-663

  Zificsak, Craig A ^a   Theroff, Jay P ^a   Aimone, Lisa D ^a   Albom, Mark S ^a   Angeles, Thelma S ^a   Brown, Rebecca A ^a   Galinis, Deborah ^a   Grobelny, Jennifer V ^a   Herbertz, Torsten ^a   Husten, Jean ^a   Kocsis, Laura S ^a   Losardo, Christine ^a   Miknyoczki, Sheila J ^a   Murthy, Seetha ^a   Rolon Steele, Damaris ^a   Underiner, Ted L ^a   Wells Knecht, Kevin J ^a   Worrell, Candace S ^a   Zeigler, Kelli S ^a   Dorsey, Bruce D ^a  

^a CEPHALON INC   (United States)

Author keywords

c Met; Diaminopyrimidine; Inhibitors; Kinase

Indexed keywords

2,4 DIAMINOPYRIMIDINE DERIVATIVE; 4 AMINOBENZAMIDE; ANILINE DERIVATIVE; DRUG METABOLITE; NITROGEN; PROTEIN KINASE INHIBITOR; SCATTER FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CANCER INHIBITION; CANCER REGRESSION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG SELECTIVITY; ENZYME PHOSPHORYLATION; IC 50; MOUSE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; TUMOR XENOGRAFT;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; MICE; MICE, NUDE; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; PYRIMIDINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78651255355     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.12.013     Document Type: Article

References (13)

1. C. Birchmeier, W. Birchmeier, E. Gherardi, and G.F. Vande Woude Nat. Rev. Mol. Cell Biol. 4 2003 915
2. J.G. Christensen, J. Burrows, and R. Salgia Cancer Lett. 225 2005 1
3. M. Mazzone, and P.M. Comoglio FASEB J. 20 2006 1611
4. For reviews of c-Met inhibitors in development, see: X. Liu, R.C. Newton, and P.A. Scherle Trends Mol. Med. 16 2010 37
5. T.L. Underiner, T. Herbertz, and S.J. Miknyoczki Anti-Cancer Agents Med. Chem. 10 2010 7
6. T.-J. Liu, T. LaFortune, T. Honda, O. Ohmori, S. Hatakeyama, T. Meyer, D. Jackson, J. de Groot, and W.K.A. Yung Mol. Cancer Ther. 6 2007 1357
7. Weinberg, L. R.; Albom, M. S.; Angeles, T. S.; Diebold, J. L.; Husten, J.; McHugh, R. J.; Lisko, J. G.; Milkiewicz, K. L.; Murthy, S.; Ott, G. R.; Ruggeri, B. A.; Theroff, J. P.; Tripathy, R.; Underiner, T. L.; Zificsak, C. A.; Dorsey, B. D. Bioorg. Med. Chem. Lett. 2010. doi: 10.1016/j.bmcl.2010.11.045.
8. A.V. Galkin, J.S. Melnick, S. Kim, T.L. Hood, N. Li, L. Li, G. Xia, R. Steensma, G. Chopiuk, J. Jiang, Y. Wan, P. Ding, Y. Liu, F. Sun, P.G. Schultz, N.S. Gray, and M. Warmuth Proc. Natl. Acad. Sci. U.S.A. 104 2007 270
9. Assay descriptions can be found in the Supplementary data.
10. As a key regulator of glucose metabolism, selectivity against IR was desired to be >10-fold in the enzymatic assays.
11. M.A. Fabian, W.H. Biggs III, D.K. Treiber, C.R. Atteridge, M.D. Azimioara, M.G. Benedetti, T.A. Carter, P. Ciceri, P.T. Edeen, M. Floyd, J.M. Ford, M. Galvin, J.L. Gerlach, R.M. Grotzfeld, S. Herrgard, D.E. Insko, M.A. Insko, A.G. Lai, J.-M. Lelias, S.A. Mehta, Z.V. Milanov, A.M. Velasco, L.M. Wodicka, H.K. Patel, P.P. Zarrinkar, and D.J. Lockhart Nat. Biotechnol. 23 2005 329
12. J. Sam, J.L. Valentine, and M.N. Aboul-Enein J. Pharm. Sci. 60 1971 1370
13. 3/MeOH to furnish 17h.